Skip to main content

Table 1 Table 1

From: Canadian ENHANCE data support the efficacy and safety of drotrecogin alfa (activated) despite higher disease severity than the global ENHANCE population

Baseline characteristics and outcomes

Canadian ENHANCE (n = 305)

Global ENHANCE (n = 2378)

Mean age, years (SD)

56.9 (17.2)

59.1 (16.9)

APACHE II ICU (SD)

25.3 (7.8)

22.0 (7.4)

# Organ failure (SD)

3.1 (1.2)

2.7 (1.1)

Baseline SOFA (SD)

10.9 (3.6)

9.7 (3.5)

Vasopressor use (%)

82%

74%

Mechanical ventilation (%)

90%

82%

Infusion serious bleed (%)

2.0%

3.6%

28-Day serious bleed (%)

3.9%

6.5%

Infusion ICH (%)

0.3%

0.6%

28-Day mortality (%)

22.6%

25.3%

  1. SD, standard deviation.